Lemon juice recommended if suffering from Hepatitis C

[nabilpk]

Is Lemon Juice recommended if suffering from Hep C?

[Rockerforlife]

I always err on the side of caution,especially when my life depeds on it....no lemons or limes for me...wait a minute....i just finshed 2 years of TX....i think ill eat a box of lems tonite and celebrate

[Rockerforlife]

You are a great researcher of information

[Rockerforlife]

You requested the link to the info on citrus fruits and the PI drugs.

[Marcia2202]

omg... I was referring to

'My doc just wants me to eat grass and drink water '

[Marcia2202]

You crack me up, thanks for the laugh.... It sure sounds like mooooo to me

[CoWriter]

"The only citrus that should be avoided when taking  meds is grapefruit. "
----------------------

There are many others.......

"POTENT INHIBITION BY STAR FRUIT OF HUMAN CYTOCHROME P450 3A (CYP3A) ACTIVITY"

http://dmd.aspetjournals.org/cgi/content/abstract/32/6/581?ijkey=3142833449ed0472aa65ca659aaecdd53316e051&keytype2=tf_ipsecsha


Inhibitory effect of fruit juices on CYP3A activity.

"The inhibitory potential of human CYP3A was in the order: grapefruit > black mulberry > wild grape >pomegranate > black raspberry."

http://dmd.aspetjournals.org/cgi/content/abstract/34/4/521?ijkey=8fc3bc688dccea368d29077e08e6a92230856feb&keytype2=tf_ipsecsha


Grapefruit juice inhibits CYP3A.  If you take any medications that are metabolized by CYP43A, inhibiting CYP3A with grapefruit juice can increase the blood level of those meds.

Telepravir and Boceprevir are metabolized by CYP3A.  So inhibiting CYP3A with grapefruit juice (or other citrus juices) will increase the blood levels of Telepravir and Boceprevir.  The drug Ritonavir also inhibits CYP3A and when they used it together with Telaprevir, the drug levels of Telaprevir increased by 15 fold.

Co


Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.

Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, Lau YY, Chovan LE, Guan Z, Hernandez L, Turner TM, Dandliker PJ, Marsh KC.

Inhibitors of hepatitis C virus (HCV) protease have shown marked antiviral activity in short-term clinical studies in HCV-infected individuals. The interaction of the investigational HCV protease inhibitors VX-950 and SCH 503034 with ritonavir, a potent inhibitor of cytochrome P450 3A, was studied in vitro and in vivo. In rat and human liver microsomes, the metabolism of VX-950 and SCH 503034 was strongly inhibited by the presence of 4 microM ritonavir. Upon co-dosing either VX-950 or SCH 503034 with ritonavir in rats, plasma exposure of the HCV protease inhibitors was increased by > 15-fold, and plasma concentrations 8 h after dosing were increased by > 50-fold.